NSD3 and cancer: To test the activity of these GOF mutants in cancer cells, Li et al. depleted NSD2 and NSD3 in human bone osteosarcoma cell line U2OS and head and neck squamous cell carcinoma (HNSCC) cell line UD-SCC-2, respectively, which led to decreased H3K36me2 expression and cell proliferation.